Material and Methods: The charts of 38 patients treated with intravitreal dexamethasone implant due to macular edema related to retinal vein occlusions between 1 May 2013 and 1 September 2014 in Trakya University Ophthalmology Department were retrospectively evaluated.

Results: In 23 patients with branch retinal vein occlusion (BRVO), while 15 had central retinal vein occlusion (CRVO). Mean age was 66.47±9.48; 17 men (%44.7) and 21 women (%55.3) patients were available. Postinjection best corrected visual acuity (BCVA) was better than preinjection at each visit in BRVO patients (p‹0.05). Postinjection central macular thickness (CMT) was thinner than preinjection and statistically significant at postinjection 1 day, 1 week, 1 month, 2 month, 3 month and 6 month (p‹0.05). BCVA increased statistically significant to preinjection at postinjection 1 week, 1 month and 2 month in CRVO patients (p‹0.05). BCVA was reduced at postinjection 3 months, gradually increased going from 4 to 6 months also showed no statistically significant difference compared to preinjection (p›0.05). CMT decreased incipiently postinjection 1 day to postinjection 2 month and thickness reduction was statistically significant at postinjection 1 day, 1 week, 1month and 2 month (p‹0.05). Medical therapy was adequate in patients with intraocular pressure rising and one patient underwent cataract surgery.

Results: It is shown intravitreal dexamethasone implant is effective and safe in treatment of macular edema related to retinal vein occlusions. Keywords : Intravitreal dexamethasone implant, macular edema, retinal vein occlusion